Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/C

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

Related Keywords

Canada , Quebec , Bristol Myers Squibb Medarex , Neoadjuvant Opdivo , Kaplan Meier , Xenetic Biosciences , Jonathand Spicer , Astrazeneca , Bristol Myers Squibb , Mcgill University Health Centre , Pfizer , Novartis , Amgen , Protalix Biotherapeutics , New England Journal , Bristol Myers ,